The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis.
This article is part I of a series. View parts II and III:Evolving Paradigms in Triple-Negative Breast Cancer> >
The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis. Patients and physicians are limited to chemotherapy that targets DNA repair complexes,p53, and cell proliferation by using anthracyclinebased, platinum-based, and taxane-based treatment regimens.1However, research into targeted therapies for TNBC is robust. Further understanding of gene expression in breast cancer has led to classifications in TNBC that may help guide research into targeted therapies.16The ultimate goal is to develop personalized, targeted treatments for TNBC. However, this requires a deep understanding of the interaction of the immune system, oncogenic pathways, and the microenvironments of the tumor.80 Understanding the etiology and ultimately prevention of TNBC requires further research using population-based studies.5
New research and the potential for targeted, personalized treatment in TNBC allow room for some optimism. However, because TNBC represents a subset of breast cancer, this requires collaboration in trials and research in order to address TNBC on a large scale.91
Click here for references:Evolving Paradigms in Triple-Negative Breast Cancer: References> >
Need for Greater Attention to Cybersecurity
May 22nd 2024Change Healthcare, owned by UnitedHealth Group, was targeted by cybercriminals, affecting 140 million Americans and costing $1 billion daily. Recovery efforts underscore the critical need for robust cybersecurity measures in healthcare.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Inavolisib Regimen Wins FDA Breakthrough Therapy Designation for PIK3CA+ Breast Cancer
May 21st 2024Data from the phase 3 INAVO120 trial support the breakthrough therapy designation granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of PIK3CA-mutated breast cancer.
Read More